Cohance Lifesciences Ltd.

NSE: COHANCE | BSE: 543064 | ISIN: INE03QK01018 | Industry: Pharmaceuticals
| Expensive Performer
431.5000 2.75 (0.64%)
NSE May 29, 2026 15:31 PM
Volume: 609.2K
 

431.50
0.64%
ICICI Securities Limited
Q2 results were lower than I-direct estimates on margin and profitability front. Revenues were in line with I-direct estimates. Despite pandemic and high base, the company has guided 15-20% growth based on strong order book position (albeit some expected delays). Regarding the optically high capex plan of | 600 crore for modernisation and technology upgradation, we believe this has to do with the need to cater to the changed priorities and requirements at the behest of the clients, the benefits of which may be visible in the long run. We continue to emphasise on the strong execution...
Number of FII/FPI investors decreased from 171 to 146 in Mar 2026 qtr
More from Cohance Lifesciences Ltd.
Recommended